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Purpose: To compare the efﬁ  cacy and tolerability of a ﬁ  xed-dose combination of 0.5% 
moxiﬂ  oxacin and 0.1% dexamethasone formulation (MFLX/DEX) vs conventional dosing 
with both agents dosed separately for prophylaxis after laser-assisted in situ keratomileusis 
(LASIK).
Methods: A prospective, randomized, double-masked, parallel-group study of 64 patients 
undergoing bilateral LASIK. Patients received either combined MFLX/DEX and placebo 
or moxiﬂ  oxacin and dexamethasone dosed separately in both eyes. Baseline and postopera-
tive assessments were made on surgery days –2, 1, 3, 8, and 15 and consisted of uncorrected 
visual acuity (UCVA), intraocular pressure (IOP), severity of inﬂ  ammation, endothelial cell 
loss, ocular pain, burning, and itching sensation. The posterior segment was evaluated at the 
screening and exit visits.
Results: Of the 64 patients treated, 7 eyes did not meet the inclusion criteria and were excluded 
from the analysis. No ocular infection or persistent inﬂ  ammation developed. Postoperatively 
there were no statistical differences between treatments for most parameters measured. More 
eyes in the combined MFLX/DEX group reported pruritus and burning post operatively; how-
ever, differences were also observed at baseline.
Conclusion: Topical prophylaxis with MFLX/DEX eye drops was well tolerated and is 
therapeutically equivalent to conventional dosing with moxiﬂ  oxacin and dexamethasone from 
individual bottles.
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Introduction
Laser-assisted in situ keratomileusis (LASIK) is the most popular operation for 
refractive correction in developed countries and one of the most common elective 
surgical procedures worldwide (Kalorama Information 2007). The surgical risks are 
low, there is little eye pain or redness postoperatively, and the visual rehabilitation 
is very fast. LASIK patients are usually prescribed antibiotic and steroid eye drops 
for the ﬁ  rst 5–14 days after surgery to prevent infection and minimize inﬂ  ammation, 
along with ad lib use of preservative-free moisturizing eye drops to combat dry eye. 
Compliance with prophylactic medications is critical to reduce the risk of serious 
complications, such as infectious keratitis.
Alcon Laboratories, Inc. has developed a new antibiotic–steroid formula-
tion consisting of 0.5% moxiﬂ  oxacin and 0.1% dexamethasone (MFLX/DEX) 
(Vigadexa®, Alcon Laboratories, Inc., Fort Worth, TX, USA). We tested this 
combination therapy in a typical LASIK population and compared its efﬁ  cacy Clinical Ophthalmology 2008:2(2) 332
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and tolerability vs conventional administration of 0.5% 
moxiﬂ  oxacin (Vigamox®, Alcon Laboratories, Inc.) and 
0.1% dexamethasone (Maxidex®, Alcon Laboratories, Inc.) 
from individual bottles.
Patients and methods
A total of 64 consecutive patients who presented for LASIK 
correction were randomly assigned to receive either the 
ﬁ  xed-dose combination of MFLX/DEX formulation and 
a dextran–methylcellulose placebo (Lacrima Plus®, Alcon 
Laboratories, Inc.) or conventional dosing with 0.5% 
moxiﬂ  oxacin and 0.1% dexamethasone solutions in indi-
vidual bottles. The combination MFLX/DEX formulation 
contained moxiﬂ  oxacin hydrochloride, dexamethasone 
sodium phosphate, edetate disodium (chelating agent), 
sodium chloride, boric acid, sorbitol, and tyloxapol (as 
surfactant).
Group assignment was masked from the patients as well 
as the researchers and clinic staff. Sixty-one patients (121 
eyes) met the protocol inclusion/exclusion criteria, including 
60 eyes randomized to the combination agent and 61 eyes 
randomized to separate dosing of both drugs. The study pro-
tocol was approved by an independent institutional review 
board and informed consent was obtained from each patient 
prior to participation in the study.
The protocol inclusion criteria consisted of men and 
women of any race who were 18–50 years old, had either 
myopia of up to –8.0 D or hyperopia of up to +4.0 D, with or 
without astigmatism of up to 3.0 D, and whose dilated fun-
duscopy at the time of enrollment was within normal limits. 
Patients were excluded from the study if they had (a) used 
topical or systemic steroids or nonsteroidal anti-inﬂ  amma-
tory drugs (NSAID) in the 14 days before enrollment (except 
aspirin, which was allowed up to 100 mg daily); (b) used 
ocular antimicrobial drugs within 30 days of enrollment; (c) 
active inﬂ  ammation on slit-lamp biomicroscopy or history 
of chronic or recurrent ocular inﬂ  ammatory disease; (d) sig-
niﬁ  cant ocular pain; (e) uncontrolled glaucoma or intraocular 
hypertension; (f) uncontrolled diabetes mellitus, proliferative 
diabetic retinopathy, or moderately severe nonproliferative 
diabetic retinopathy; (g) known or suspected allergy to any of 
the drugs or preservatives to be used in the study; (h) active 
epithelial herpes simplex, vaccinia, chicken pox, corneal or 
conjunctival disease, ocular tuberculosis or fungal disease; 
(i) intraocular pressure measurements greater than 20 mmHg; 
(j) participated in a clinical trial within 12 months of enroll-
ment; (k) any severe systemic disease or condition that made 
self-treatment with eye drops difﬁ  cult; (l) sight in a single 
eye; (m) or best-corrected visual acuity (BCVA) worse than 
1.0 on the logMAR scale. Pregnant or lactating women or 
women of childbearing age not using reliable birth control 
methods were also excluded. Patients who were receiving 
a topical prostaglandin for IOP control were instructed to 
discontinue its use at least 4 days prior to surgery and until 
the study was completed. All surgical candidates were told 
to stop wearing contact lenses for at least 2 weeks before the 
LASIK procedure.
Bilateral, simultaneous, wavefront-guided LASIK was 
performed using the LADARVision system (Alcon Labo-
ratories, Inc.). Patients in the combined MFLX/DEX treat-
ment group received two opaque bottles, one containing the 
moxiﬂ  oxacin–dexamethasone solution and the other placebo. 
Patients in the control group also received two opaque 
bottles, one bottle containing moxiﬂ  oxacin and the other 
dexamethasone. All patients were instructed to apply 1 drop 
from each bottle in both eyes 4 times a day, waiting 5 minutes 
between drops, beginning 15 minutes after completion of the 
procedure and continuing until the 15th day.
Two days before surgery (Day –2), the baseline values 
were recorded for visual acuity (VA), IOP, number of cells in 
the anterior chamber, clinical impression of inﬂ  ammation of 
eyelids and conjunctiva, ocular pain, burning or itching sensa-
tion, and fundus status. These assessments were repeated on 
the ﬁ  rst day after surgery (Day 1) and thereafter on days 3, 8, 
and 15, except for dilated funduscopy, which was performed 
only at the screening and exit visits.
The visual acuity was determined with an ETDRS or 
modiﬁ  ed ETDRS chart and expressed in logMAR values. 
Preoperatively, all patients had a BCVA of 0.0 logMAR, 
while postoperatively the vision was measured uncorrected. 
The IOP readings were taken with the Goldmann Applana-
tion Tonometer. Slit-lamp biomicroscopy was used to count 
the number of cells in the anterior chamber; a score of 0   5 
cells; 1 = 5–10 cells; 2 = 11–20 cells; 3 = 21–50 cells; and 
4   50 cells. Any visible sign of active ocular inﬂ  ammation – 
redness, swelling, tearing, or discharge – was documented. 
The patients were asked to subjectively rank their eye pain 
on a 5-point scale, from 0 = none to 5 = severe. Sensations of 
ocular burning and pruritus were recorded as yes or no. The 
fundus was visualized through a dilated pupil on Day –2 and 
Day 15. All evaluations were made binocularly.
Seven eyes were excluded from the per-protocol analysis: 
6 eyes of 3 patients older than 50 years and 1 eye of 1 patient 
whose astigmatism was higher than 3 diopters. Statistical 
analysis was performed on the remaining 121 eyes by means 
of Mann-Whitney and chi-square tests, non-paired t tests, and Clinical Ophthalmology 2008:2(2) 333
Moxiﬂ  oxacin – dexamethasone formulation for LASIK
variance analysis (ANOVA) with two-tailed testing at a 5% 
conﬁ  dence level (p = 0.05).
Results
At randomization the treatment groups were similar for age, 
sex, and race. Seven eyes of 4 patients were excluded from 
the per protocol analysis. Demographics for the remaining 61 
patients (121 eyes) are presented in Table 1. Both groups were 
matched for gender and race. The median age of patients in the 
combined MFLX/DEX group was slightly lower than in the 
separate moxiﬂ  oxacin and dexamethasone group. There were 
more women than men in our study population. Two patients 
(3 eyes) in the moxiﬂ  oxacin and dexamethasone separate group 
experienced surgical problems. One patient had minor bleeding 
in both eyes during the LASIK procedure and 1 patient had a 
thin ﬂ  ap in the left eye. All eyes in the combined treatment 
group were myopic and had astigmatism. Among those receiv-
ing separate antibiotic and anti-inﬂ  ammatory eye drops, 29 eyes 
were myopic, 3 were hyperopic, and 27 had astigmatism. The 
maximum refractive error allowed in the study was –8.0 D to 
+4.0 D with up to 3.0 D of cylinder. All evaluable patients (121 
eyes) remained in the study through the Day 15 exit visit.
Both groups had similar postoperative improvement in 
visual acuity. The median UCVA at each visit was no differ-
ent between treatments. A median UCVA of –0.10 and –0.06 
on the logMAR scale was reported for the MFLX/DEX 
combined and the moxiﬂ  oxacin and dexamethasone separate 
groups, respectively, by Day 15.
The intraocular pressure ﬂ  uctuated curiously throughout 
the study, sometimes within the same eyes in a 48-hour period. 
When the median intraocular pressure was calculated, however, 
there was no statistical difference between the treatment groups. 
For the baseline visit and ﬁ  rst week after surgery (up to Day 8), 
the IOP ranged from a minimum of 7 mmHg to a maximum of 
18 mmHg. On Day 15, an IOP spike to 28 mmHg was recorded 
in both eyes of 1 patient in the combined MFLX/DEX treatment 
group. The patient was started on timolol every 12 hours and 
rechecked 6 days later, at which time the IOP was 10 mmHg 
and the timolol was stopped. Off medication, her intraocular 
pressure remained within normal limits on subsequent visits.
As expected, there was no endothelial cell loss second-
ary to the keratomileusis. Fewer than 5 cells were recorded 
in the anterior chamber at any time regardless of treatment. 
Clinical examination was also negative for any injection or 
evidence of inﬂ  ammation in the eyelids, conjunctiva, and 
sclera. On Day 1, 3 eyes in the combined MFLX/DEX group 
and 5 eyes in the moxiﬂ  oxacin and dexamethasone separate 
group showed minor structural changes, inﬁ  ltrate, or edema 
on biomicroscopy. These ﬁ  ndings persisted in 1 eye for the 
ﬁ  rst week, but by Day 15 all corneas were clear.
With regard to eye pain, no statistically signiﬁ  cant differ-
ences were observed between the MFLX/DEX combined and 
the moxiﬂ  oxacin and dexamethasone separate groups. Ocular 
pain was rated as “none”, “minimal”, or “mild”, except for 
a single eye in the combined MFLX/DEX group that was 
reported as “moderately severe” on Day 8 (Figure 1). Careful 
examination revealed no obvious cause for the pain, which 
was relieved without analgesics within a few hours.
A burning sensation was reported in more study eyes in the 
MFLX/DEX combined group compared with the moxiﬂ  oxacin 
and dexamethasone separate group at Day 1 (12 eyes vs 1 eye, 
respectively), but at baseline more eyes had ocular burning in 
the combined MFLX/DEX group. At Day 15, both groups had 
equal numbers (8) of eyes with burning (Figure 2). More patients 
who received combination MFLX/DEX therapy complained 
of itching eyes prior to LASIK than in the moxiﬂ  oxacin and 
dexamethasone separate group (16 eyes vs 0 eyes, p   0.001, 
respectively). This difference between treatment groups per-
sisted following surgery and was statistically signiﬁ  cant on 
Day 1, and Day 15 postoperative (15 eyes vs 3 eyes at Day 1, 
p   0.0019, and 15 eyes vs 4 eyes at Day 15, p   0.0053, for 
the combined MFLX/DEX group and moxiﬂ  oxacin and dexa-
methasone separate group, respectively) (Figure 3). When the 
data were analyzed excluding patients with pruritus at baseline, 
there were no differences between treatment groups in postop-
erative ocular pruritus (Day 1, 7 eyes vs 3 eyes; Day 3, 10 eyes 
Table 1 Patient demographics
 MFLX/DEX  MFLX  and  DEX 
 combined    separate 
 N  = 30 N  = 31
Age (years)     
 Mean  29.1  32.9 
 Median  28.5  31.0  p = 0.033
Gender      
 Femalea 22  22 
 Male  8  9  p = 0.8368
Race       
 Caucasianb 25  25 
 African  1  0 
 Asian  2  2 
 Mulatto  2  4  p = 0.7848
Surgical      
problems
 No  30  29 
 Yes  0  2c 
aFemale vs male, χ2 = 0.04.
bCaucasian vs others, χ2 = 0.07.
cOne patient had minor bleeding in both eyes and one patient had a thin ﬂ  ap in the 
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vs 12 eyes; Day 8, 2 eyes vs 6 eyes; and Day 15, 11 eyes vs 
4 eyes; for the combined MFLX/DEX and moxiﬂ  oxacin and 
dexamethasone separate groups, respectively) (p   0.05).
Dilated funduscopy showed normal vitreous, retina, 
macula, and choroid of all eyes at all times. There were no 
adverse events reported related to study medication.
Discussion
Ocular infection is a dreaded complication of any ophthal-
mic procedure, particularly after an elective surgery such 
as LASIK. Although endophthalmitis is fortunately rare in 
LASIK and infectious keratitis has a low incidence (up to 
1.5%) (Chang et al 2004; Solomon et al 2003), infection of 
any kind can have devastating consequences to visual func-
tion and every step should be taken to prevent it (Solomon 
and Donnenfeld 2005). The majority of keratitis cases are 
noninfectious and are diagnosed as diffuse lamellar keratitis 
(DLK) (Moshirfar et al 2007). DLK is characterized by an 
ill-deﬁ  ned, widespread inﬂ  ammatory reaction at the ﬂ  ap 
interface (Alio et al 2000) and diffuse, multifocal, sterile 
Figure 1 Ocular pain by treatment group. Comparison of ocular pain scores at baseline (Day –2) and each postoperative visit for MFLX/DEX combined and MFLX and DEX 
dosed separately.
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corneal inﬁ  ltrates (Smith and Maloney 1998; Lifshitz et al 
2005). DLK shows a strong association with epithelial defects 
and anterior chamber reactions developing after LASIK 
(Shah et al 2000; Johnson et al 2001; Chang et al 2004; 
Moilanen et al 2004).
Many practitioners opt for peri-LASIK prophylaxis with 
an antibiotic solution – usually a fourth-generation ﬂ  uoro-
quinolone (Solomon and Donnenfeld 2005) – and a topical 
steroid, such as prednisolone or dexamethasone, to control 
the initial corneal inﬂ  ammation that sometimes leads to more 
serious keratitis. Patients are typically instructed to apply the 
eye drops at 5-minute intervals 4 times a day for at least 5 
days after LASIK.
Several studies have established the safety and effective-
ness of moxiﬂ  oxacin in the prevention and treatment of infec-
tious bacterial keratitis, including that of mycobacterial origin 
(Kowalski et al 2003; Abshire et al 2004; Lee et al 2005; 
Durrie and Trattler 2005; Yee et al 2006; Solomon et al 2007). 
Likewise, dexamethasone has a long and reliable history as 
a useful anti-inﬂ  ammatory adjuvant in cataract surgery (van 
Endt et al 1997; Notivol et al 2004; Russo et al 2007) with 
no adverse effect on the corneal epithelium (Gris et al 2004; 
Yulek et al 2006). The present study evaluated a ﬁ  xed-dose 
combination product of moxiﬂ  oxacin and dexamethasone in 
patients undergoing LASIK.
We monitored patients who underwent bilateral LASIK 
to check for signs of infection and inﬂ  ammation under two 
drug regimens; half of the patients were given eye drops 
containing a ﬁ  xed-dose combination of 0.5% moxiﬂ  oxacin 
with 0.1% dexamethasone and a placebo and half received 
same-strength moxifloxacin and dexamethasone in the 
conventional manner from individual bottles. No infection 
developed and there was no corneal inﬂ  ammation beyond 
the initial postoperative period. Results for UCVA, IOP, 
Figure 2 Burning/stinging sensation in eye by treatment group. Comparison of burning/stinging scores at baseline (Day –2) and each postoperative visit for MFLX/DEX 
combined and MFLX and DEX dosed separately. Burning and stinging scores in each eye were rated as either “yes” or “no”.
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endothelial cell count, slit lamp, and fundus evaluation were 
similar for patients treated with the combination eye drops 
or the separate medications. One patient had an isolated 
rise in intraocular pressure bilaterally that was unexplained. 
After a short course of timolol, her IOP returned to normal 
levels and has remained in the 10–12 mmHg range over the 
ensuing months.
The combination of moxiﬂ  oxacin and dexamethasone 
in a single vehicle simpliﬁ  es eye-drop application and is 
expected to improve patient compliance with treatment 
(Ermis et al 2004). From an economical standpoint, the 
combination product reduces medication cost since patients 
only need to purchase a single bottle of medication instead 
of two separate bottles.
Decreasing the complexity of dosing and the number of 
separately administered ophthalmic medications is likely to 
decrease dosing errors and noncompliance following LASIK. 
Compliance with topical ocular glaucoma medications has 
been shown to decrease when patients were changed from a 
single medication regimen to a regimen of two medications 
(Patel and Spaeth 1995). Similarly, the addition of a second 
non-once-daily medication was also associated with an 
increase in percentage of dosage errors (37%) in a short-term 
(60 days) adherence study in glaucoma patients (Robin et al 
2007). Although one may argue that patient compliance fol-
lowing LASIK surgery differs because the treatment course is 
shorter and there is greater patient motivation for this elective 
procedure, the prophylactic drug regimens following LASIK 
surgery are more complex than those for glaucoma treatment, 
increasing the likelihood of inadvertent dosing errors.
The use of a combination product has also been shown 
to positively impact clinical outcomes. For example, greater 
IOP lowering was demonstrated with ﬁ  xed-dose combined 
dorzolamide-timolol drops compared with both agents 
Figure 3 Ocular itching by treatment group. Comparison of itching scores at baseline (Day –2) and each postoperative visit for MFLX/DEX combined and MFLX and DEX 
dosed separately. Ocular itching scores in each eye were rated as either “yes” or “no”.
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dosed separately. Greater efﬁ  cacy was attributed to better 
patient compliance and/or to decreased medication washout 
(Choudhri et al 2000).
Medication washout occurs when more than one topical 
ocular medication is dosed at the same time of day. Administer-
ing a second topical ocular product too close in time to the ﬁ  rst 
can reduce the amount of the ﬁ  rst drug delivered to the eye, such 
that if a patient waits less than 5 minutes between medications, 
a signiﬁ  cant proportion is washed out by the second (Chrai 
et al 1974). Given that LASIK patients must administer two 
or three different prophylactic ocular medications at similar 
dosing intervals, the time to administer these agents (including 
waiting time) can be as long as 15 minutes.
Certain ﬁ  ndings from the present study remain unex-
plained. A single patient in the combined MFLX/DEX 
treatment group reported moderately severe pain in 1 eye 
on Day 8. We could ﬁ  nd no physical cause for the pain 
and it resolved within 24 hours without speciﬁ  c treatment. 
Two weeks after surgery, more patients in both treatment 
groups complained of ocular discomfort than before the 
procedure, though the sensation was ill-deﬁ  ned and only 
minimally uncomfortable. LASIK, like all eye surgeries, 
involves controlled trauma to the ocular tissues followed 
by a period of recovery and healing. In this study, regard-
less of treatment group, only a small percentage of patients 
reported mild discomfort
More patients taking the combination MFLX/DEX 
drops complained of itching after LASIK. Upon further 
inspection of the data it was determined that these were the 
same patients who complained of ocular pruritus before 
the LASIK procedure, and we believe this ﬁ  nding reﬂ  ects 
the cohort’s idiosyncrasies, independent of the medication 
received. There were no adverse reactions related to either 
drug regimen and all patients appeared to tolerate the eye 
drops very well.
Conclusion
A ﬁ  xed-dose formulation of moxiﬂ  oxacin and dexametha-
sone was found to be safe and effective in preventing 
infection and controlling inﬂ  ammation post-LASIK. The 
combined antibiotic–anti-inﬂ  ammatory eye drop solution 
was therapeutically equivalent to conventional therapy with 
individual bottles of moxiﬂ  oxacin and dexamethasone in 
this population.
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